Statistics

Total Visits

Views
Early tumour shrinkage (ETS) and depth of response (DpR) with first-line panitumumab (P) plus FOLFOX4 (P-FOLFOX4) or FOLFIRI (P-FOLFIRI) in patients (pts) with wild-type (WT) RAS colorectal cancer (CRC) and liver-limited disease (LLD)70

Select a period of time:

Number of views in the range

Views
Early tumour shrinkage (ETS) and depth of response (DpR) with first-line panitumumab (P) plus FOLFOX4 (P-FOLFOX4) or FOLFIRI (P-FOLFIRI) in patients (pts) with wild-type (WT) RAS colorectal cancer (CRC) and liver-limited disease (LLD)9

Views

Views
May 20253
June 20250
July 20254
August 20250
September 20250
October 20251
November 20251
Download CSV file
 untranslated
 untranslated

Top country views

Views
United States4
United Kingdom2
Argentina1
Brazil1
Algeria1
 

Top cities views

Views
Algiers1
Alliance1
Beckenham1
Comodoro Rivadavia1
Goiânia1
Los Angeles1
Orlando1